ITUA20162292A1 - Uso del tamoxifene per il trattamento della fibrosi cistica in pazienti di entrambi i sessi - Google Patents

Uso del tamoxifene per il trattamento della fibrosi cistica in pazienti di entrambi i sessi

Info

Publication number
ITUA20162292A1
ITUA20162292A1 ITUA2016A002292A ITUA20162292A ITUA20162292A1 IT UA20162292 A1 ITUA20162292 A1 IT UA20162292A1 IT UA2016A002292 A ITUA2016A002292 A IT UA2016A002292A IT UA20162292 A ITUA20162292 A IT UA20162292A IT UA20162292 A1 ITUA20162292 A1 IT UA20162292A1
Authority
IT
Italy
Prior art keywords
sexes
tamoxifen
patients
treatment
cystic fibrosis
Prior art date
Application number
ITUA2016A002292A
Other languages
English (en)
Inventor
Giorgio Balduzzi
Original Assignee
Gb Pharma S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gb Pharma S R L filed Critical Gb Pharma S R L
Priority to ITUA2016A002292A priority Critical patent/ITUA20162292A1/it
Priority to EA201891911A priority patent/EA036682B1/ru
Priority to PL17715154.5T priority patent/PL3439645T3/pl
Priority to ES17715154T priority patent/ES2951263T3/es
Priority to PCT/EP2017/057895 priority patent/WO2017174529A1/en
Priority to HUE17715154A priority patent/HUE064521T2/hu
Priority to CN201780021545.2A priority patent/CN109310652A/zh
Priority to RS20230888A priority patent/RS64640B1/sr
Priority to EP17715154.5A priority patent/EP3439645B1/en
Priority to CA3018024A priority patent/CA3018024A1/en
Priority to HRP20231197TT priority patent/HRP20231197T1/hr
Priority to JP2018552700A priority patent/JP2019510791A/ja
Priority to US16/089,528 priority patent/US11191738B2/en
Publication of ITUA20162292A1 publication Critical patent/ITUA20162292A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ITUA2016A002292A 2016-04-05 2016-04-05 Uso del tamoxifene per il trattamento della fibrosi cistica in pazienti di entrambi i sessi ITUA20162292A1 (it)

Priority Applications (13)

Application Number Priority Date Filing Date Title
ITUA2016A002292A ITUA20162292A1 (it) 2016-04-05 2016-04-05 Uso del tamoxifene per il trattamento della fibrosi cistica in pazienti di entrambi i sessi
EA201891911A EA036682B1 (ru) 2016-04-05 2017-04-03 Применение тамоксифена для лечения кистозного фиброза у пациентов обоих полов
PL17715154.5T PL3439645T3 (pl) 2016-04-05 2017-04-03 Stosowanie tamoksyfenu w leczeniu mukowiscydozy u pacjentów płci innej niż żeńska
ES17715154T ES2951263T3 (es) 2016-04-05 2017-04-03 Uso de tamoxifeno para el tratamiento de la fibrosis quística en pacientes que no son mujeres
PCT/EP2017/057895 WO2017174529A1 (en) 2016-04-05 2017-04-03 Use of tamoxifen for the treatment of cystic fibrosis in patients of both sexes
HUE17715154A HUE064521T2 (hu) 2016-04-05 2017-04-03 Tamoxifen alkalmazása cisztás fibrózis kezelésére nem nõi pácienseknél
CN201780021545.2A CN109310652A (zh) 2016-04-05 2017-04-03 它莫昔芬在治疗两性患者的囊性纤维化中的用途
RS20230888A RS64640B1 (sr) 2016-04-05 2017-04-03 Upotreba tamoksifena za lečenje cistične fibroze kod pacijenata koji nisu žene
EP17715154.5A EP3439645B1 (en) 2016-04-05 2017-04-03 Use of tamoxifen for the treatment of cystic fibrosis in non-female patients
CA3018024A CA3018024A1 (en) 2016-04-05 2017-04-03 Use of tamoxifen for the treatment of cystic fibrosis in patients of both sexes
HRP20231197TT HRP20231197T1 (hr) 2016-04-05 2017-04-03 Uporaba tamoksifena za liječenje cistične fibroze kod pacijenata koji nisu žene
JP2018552700A JP2019510791A (ja) 2016-04-05 2017-04-03 両性の患者における嚢胞性線維症の治療のためのタモキシフェンの使用
US16/089,528 US11191738B2 (en) 2016-04-05 2017-04-03 Use of tamoxifen for the treatment of cystic fibrosis in patients of both sexes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITUA2016A002292A ITUA20162292A1 (it) 2016-04-05 2016-04-05 Uso del tamoxifene per il trattamento della fibrosi cistica in pazienti di entrambi i sessi

Publications (1)

Publication Number Publication Date
ITUA20162292A1 true ITUA20162292A1 (it) 2017-10-05

Family

ID=56551460

Family Applications (1)

Application Number Title Priority Date Filing Date
ITUA2016A002292A ITUA20162292A1 (it) 2016-04-05 2016-04-05 Uso del tamoxifene per il trattamento della fibrosi cistica in pazienti di entrambi i sessi

Country Status (13)

Country Link
US (1) US11191738B2 (it)
EP (1) EP3439645B1 (it)
JP (1) JP2019510791A (it)
CN (1) CN109310652A (it)
CA (1) CA3018024A1 (it)
EA (1) EA036682B1 (it)
ES (1) ES2951263T3 (it)
HR (1) HRP20231197T1 (it)
HU (1) HUE064521T2 (it)
IT (1) ITUA20162292A1 (it)
PL (1) PL3439645T3 (it)
RS (1) RS64640B1 (it)
WO (1) WO2017174529A1 (it)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009105234A2 (en) * 2008-02-19 2009-08-27 Combinatorx, Incorporated Methods and compositions for the treatment of disorders associated with defects of the cystic fibrosis transmembrane conductance regulator gene or protein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2174388T3 (es) * 1997-06-27 2002-11-01 Akzo Nobel Nv Solucion liquida de medicamento para administracion oral.
WO2012134965A1 (en) 2011-03-25 2012-10-04 The Trustees Of Columbia University In The City Of New York Chloride channel and chloride transporter modulators for therapy in smooth muscle diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009105234A2 (en) * 2008-02-19 2009-08-27 Combinatorx, Incorporated Methods and compositions for the treatment of disorders associated with defects of the cystic fibrosis transmembrane conductance regulator gene or protein

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ACHIM D. GRUBER ET AL: "Molecular cloning and transmembrane structure of hCLCA2 from human lung, trachea, and mammary gland", AMERICAN JOURNAL OF PHYSIOLOGY - CELL PHYSIOLOGY, 1 June 1999 (1999-06-01), UNITED STATES, pages 1261 - 1270, XP055321637, Retrieved from the Internet <URL:http://ajpcell.physiology.org/content/276/6/C1261.full.pdf> [retrieved on 20161122] *
HEIDI LEDFORD: "Tamoxifen takes on cystic fibrosis", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 15, no. 1, 1 January 2009 (2009-01-01), pages 28, XP002665513, ISSN: 1078-8956 *
RAY D COAKLEY ET AL: "17 beta-Estradiol inhibits Ca2+-dependent homeostasis of airway surface liquid volume in human cystic fibrosis airway epithelia", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 118, no. 12, 1 December 2008 (2008-12-01), pages 4025 - 4035, XP002665514, ISSN: 0021-9738, [retrieved on 20081120], DOI: 10.1172/JCI33893 *

Also Published As

Publication number Publication date
US11191738B2 (en) 2021-12-07
RS64640B1 (sr) 2023-10-31
EP3439645C0 (en) 2023-07-05
WO2017174529A1 (en) 2017-10-12
JP2019510791A (ja) 2019-04-18
HRP20231197T1 (hr) 2024-01-19
US20200297667A1 (en) 2020-09-24
HUE064521T2 (hu) 2024-03-28
CN109310652A (zh) 2019-02-05
EA036682B1 (ru) 2020-12-08
EP3439645B1 (en) 2023-07-05
PL3439645T3 (pl) 2023-08-21
EP3439645A1 (en) 2019-02-13
CA3018024A1 (en) 2017-10-12
ES2951263T3 (es) 2023-10-19
EA201891911A1 (ru) 2019-04-30

Similar Documents

Publication Publication Date Title
LTC3057969I2 (lt) Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit
DK3706796T3 (da) Eksosomerer som RNA terapeutikske midler
GB2548873B (en) Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
GB201621480D0 (en) Use of cannabinoids in the treatment of angelman syndrome
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
SMT201600102B (it) Tritoqualina per l’uso nel trattamento della fibrosi cistica
IT201700028184A1 (it) Composti e composizioni per il trattamento della fibrosi cistica
ES2970224T3 (es) Tinostamustina para su uso en el tratamiento del sarcoma
IL249402A0 (en) Aminoglycosides for the treatment of Rett&#39;s syndrome
DK3125874T3 (da) Et terapeutisk middel til anvendelse i behandlingen af infektioner
PL3160464T3 (pl) 6-hydroksybuspiron do stosowania w leczeniu zaburzeń ruchowych
IL246855A0 (en) Materials for use in the treatment of retinitis
SMT201700018B (it) Uso di sali di tungsteno (vi) per il trattamento della sterilità femminile in mammiferi non diabetici
DK3419673T3 (da) Genterapi til behandling af sygdom i nethindens tapceller
IT201600081379A1 (it) Composizione farmaceutica per uso nel trattamento delle patologie prostatiche.
PL3320901T3 (pl) Dimetyloaminomicheliolid do zastosowania w leczeniu włóknienia płuc
SMT201700072B (it) Utilizzo del pidotimod per il trattamento della psoriasi
HK1252811A1 (zh) 用於去勢治療相關症狀之治療的化合物
ITRM20130465A1 (it) Metodo per la diagnosi in vitro di fibrosi polmonare/polmonite interstiziale idiopatica e uso di chelanti del ferro per il trattamento della fibrosi polmonare/polmonite interstiziale idiopatica.
IT201700111939A1 (it) Composizione farmaceutica per l’uso nel trattamento di stati infiammatori
ITUA20162292A1 (it) Uso del tamoxifene per il trattamento della fibrosi cistica in pazienti di entrambi i sessi
ITUB20169937A1 (it) Formulazioni farmaceutiche e loro uso per il trattamento della retinite pigmentosa
BR112018006201A2 (pt) composições para higiene bucal e métodos de uso das composições
IT201700028127A1 (it) Composti e composizioni per il trattamento della fibrosi cistica
HUE039153T2 (hu) Kompozíciók diszlipidémia kezelésében való alkalmazásra krónikus vesebetegségnél